Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Associations Between CDR-Global and Meaningful Outcomes in Patients with Alzheimer’s Disease
Aging, Dementia, Cognitive, and Behavioral Neurology
P5 - Poster Session 5 (11:45 AM-12:45 PM)
7-010
There is a paucity of evidence describing the association between Clinical Dementia Rating Scale (CDR-global) and outcomes that are considered meaningful to patients, caregivers, clinicians and payors. 
To estimate the associations between CDR scores and meaningful outcomes (e.g., activities of daily living using Functional Assessment Scale [FAS] and other cognitive scales) in individuals followed at Alzheimer’s disease (AD) research centers. 
This retrospective study used the National Alzheimer’s Coordinating Center (NACC) Uniform Data Set (UDS), which collects yearly follow-up data from patients that are seen at participating AD research centers. The study included participants with normal cognition, mild cognitive impairment (MCI) or dementia due to AD (etiologies were determined by clinician diagnosis). The associations between the annual assessments of CDR-global and the meaningful outcomes were investigated using mixed models with unstructured covariance matrices and participant identifiers as random effects adjusting for demographics and comorbidities.
The study included participants with normal cognition (13,692 [48.5%]), MCI (7,075 [25.1%]), and dementia due to AD (7,453 [26%]). Difficulties in conducting daily activities such as writing checks, doing grocery shopping, or preparing a hot meal were observed in participants with MCI (CDR-global=0.5) and across all stages of dementia (CDR-global>1) due to AD. Further, the adjusted total baseline FAS average scores (higher values indicate worse function) were 1.7 CI [1.4, 2.0], 7.2 CI [6.9, 7.5], 18.3 CI [18.0, 18.6], 25.7 CI [25.4, 26.0] and 28.8 CI [28.4, 29.1] for normal, MCI, mild, moderate, and severe AD dementia, respectively. Similar patterns were observed for all other outcomes of interest (e.g., geriatric depression scale and Mini-Mental State Exam).

There were strong associations between CDR-stage and different measures of mental health, cognition and ability to conduct daily activities in patients with AD. CDR-global is a good proxy for abilities considered clinically meaningful in MCI and mild AD dementia.

Authors/Disclosures
Christian Wichmann (Novo Nordisk A/S)
PRESENTER
Dr. Wichmann has received personal compensation for serving as an employee of Novo Nordisk.
Merce Boada Rovira, MD, PhD (Fundació ACE. Institut Català de Neurociènces Aplicades) Dr. Boada Rovira has received personal compensation for serving as an employee of FUNDACIO ACE. ICNA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ZAMBON. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LILLY. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ZAMBON. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVO NORDISK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOIBERICA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SERVIER. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SCHWABE PHARMA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NUTRICIA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SERVIER. Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for ZAMBON.
Krista Lanctot (Sunnybrook Research Institute) Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BioXcel Therapeutics. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bright Minds. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel Therapeutics. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Co. Ltd. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Exciva. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ICG Pharma. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kondor Pharma. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for H Lundbeck A/S. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis Therapeutics. Prof. Lanctot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sumitomo Pharma Co. Ltd. Prof. Lanctot has stock in Highmark Interactive.
Pierre Tariot (Banner Alzheimer's Institute) Pierre Tariot has received personal compensation for serving as an employee of Banner Alzheimer's Institute. Pierre Tariot has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Pierre Tariot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AC Immune. Pierre Tariot has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Pierre Tariot has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for WebMD. Pierre Tariot has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arcadia. Pierre Tariot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Pierre Tariot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BioXcel. Pierre Tariot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cortexyme. Pierre Tariot has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Pierre Tariot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for eNOVA. Pierre Tariot has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Pierre Tariot has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Syneos. Pierre Tariot has received intellectual property interests from a discovery or technology relating to health care.
Firas Dabbous Firas Dabbous has stock in Abbvie, Abott Labs, Pfizer and Thermo Fisher Scientific.
Julie Hviid Hahn-Pedersen (Novo Nordisk A/S) Mrs. Hviid Hahn-Pedersen has received personal compensation for serving as an employee of Novo Nordisk A/S. Mrs. Hviid Hahn-Pedersen has stock in Novo Nordisk.
Lars Lau L. Raket, PhD (Novo Nordisk) Dr. Raket has received personal compensation for serving as an employee of Novo Nordisk A/S. Dr. Raket has received personal compensation for serving as an employee of Lundbeck.
Sariya Udayachalerm, PhD (Evidera) Dr. Udayachalerm has nothing to disclose.
Cynthia Saiontz-Martinez, Other (Evidera) Ms. Saiontz-Martinez has nothing to disclose.
Wojciech Michalak (Novo Nordisk) Mr. Michalak has received personal compensation for serving as an employee of Novo Nordisk.
Luis Rafael Solís-Tarazona, MD Mr. Solís-Tarazona has received personal compensation for serving as an employee of Novo Nordisk A/S.
Jeffrey Lee Cummings, MD, FAAN Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ACADIA. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alkahest. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Green Valley. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuaka. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for United Neuroscience. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Cummings has received research support from NIH. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.